---
title: "DaShenLin Pharmaceutical Group Co., Ltd. (603233.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/603233.SH.md"
symbol: "603233.SH"
name: "DaShenLin Pharmaceutical Group Co., Ltd."
industry: "Drug Retail"
datetime: "2026-05-20T17:14:09.638Z"
locales:
  - [en](https://longbridge.com/en/quote/603233.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/603233.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/603233.SH.md)
---

# DaShenLin Pharmaceutical Group Co., Ltd. (603233.SH)

## Company Overview

DaShenLin Pharmaceutical Group Co., Ltd. manufactures, distributes, and retails pharmaceutical products in China. It offers Chinese and Western patent medicines, ginseng and antler tonic medicinal materials, Chinese herbal medicine slices, health products, medical devices, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.

| Item | Detail |
|------|--------|
| Industry | Drug Retail |
| Exchange | CN Market |
| Website | [www.dslyy.com](https://www.dslyy.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: B (0.39)**

**Industry**: Drug Retail

| Metric | Value |
|--------|-------|
| Industry Ranking | 2 / 8 |
| Industry Median | B |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 3.07% |  |
| Net Profit YoY | 31.76% |  |
| P/B Ratio | 2.64 |  |
| Dividend Ratio | 3.63% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 20296143876.16 |  |
| Revenue | 27568381740.82 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 16.90% | A |
| Profit Margin | 4.67% | C |
| Gross Margin | 36.05% | C |
| Revenue YoY | 3.07% | C |
| Net Profit YoY | 31.76% | B |
| Total Assets YoY | 0.20% | D |
| Net Assets YoY | 6.39% | B |
| Cash Flow Margin | 353.72% | A |
| OCF YoY | 3.07% | C |
| Turnover | 1.03 | A |
| Gearing Ratio | 65.77% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - DaShenLin Pharmaceutical Group Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "3.07%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "31.76%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.64",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "3.63%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "20296143876.16",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "27568381740.82",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "16.90%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "4.67%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "36.05%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "3.07%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "31.76%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.20%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "6.39%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "353.72%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "3.07%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "1.03",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "65.77%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 15.86 | 2/8 | 19.92 | 18.66 | 17.78 |
| PB | 2.66 | 6/8 | 3.00 | 2.82 | 2.72 |
| PS (TTM) | 0.74 | 6/8 | 0.79 | 0.75 | 0.73 |
| Dividend Yield | 3.61% | 3/8 | 3.67% | 3.57% | 3.39% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Yifeng Pharmacy (603939.SH) | B | C | B | C | C | B |
| 02 | DSL (603233.SH) | B | C | A | D | B | B |
| 03 | Huaren Health (301408.SZ) | B | B | A | D | A | B |
| 04 | SYPM (301017.SZ) | C | B | A | E | A | B |
| 05 | NO.1 PHARMACY (600833.SH) | C | C | A | C | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-10T16:00:00.000Z

Total Analysts: **11**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 55% |
| Overweight | 4 | 36% |
| Hold | 1 | 9% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 17.92 |
| Highest Target | 26.70 |
| Lowest Target | 22.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/603233.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/603233.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/603233.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/603233.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**